DK3310389T3 - Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis - Google Patents
Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis Download PDFInfo
- Publication number
- DK3310389T3 DK3310389T3 DK16729470.1T DK16729470T DK3310389T3 DK 3310389 T3 DK3310389 T3 DK 3310389T3 DK 16729470 T DK16729470 T DK 16729470T DK 3310389 T3 DK3310389 T3 DK 3310389T3
- Authority
- DK
- Denmark
- Prior art keywords
- retinoid
- corticosteroid
- psoriasis
- treatment
- compositions including
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title 1
- 239000003246 corticosteroid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000004492 retinoid derivatives Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181481P | 2015-06-18 | 2015-06-18 | |
| PCT/US2016/035991 WO2016205001A1 (en) | 2015-06-18 | 2016-06-06 | Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3310389T3 true DK3310389T3 (da) | 2020-08-10 |
Family
ID=56131662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16729470.1T DK3310389T3 (da) | 2015-06-18 | 2016-06-06 | Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis |
Country Status (20)
| Country | Link |
|---|---|
| US (7) | US10251895B2 (da) |
| EP (1) | EP3310389B1 (da) |
| JP (1) | JP6997624B2 (da) |
| KR (2) | KR102643849B1 (da) |
| CN (1) | CN108282998B (da) |
| AU (1) | AU2016279801B2 (da) |
| BR (1) | BR112017027332B1 (da) |
| CA (1) | CA2988577A1 (da) |
| CY (1) | CY1123354T1 (da) |
| DK (1) | DK3310389T3 (da) |
| ES (1) | ES2812451T3 (da) |
| HR (1) | HRP20201250T1 (da) |
| HU (1) | HUE050603T2 (da) |
| LT (1) | LT3310389T (da) |
| MX (1) | MX2017015990A (da) |
| PL (1) | PL3310389T3 (da) |
| PT (1) | PT3310389T (da) |
| RS (1) | RS60672B1 (da) |
| SI (1) | SI3310389T1 (da) |
| WO (1) | WO2016205001A1 (da) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11957753B2 (en) | 2010-11-22 | 2024-04-16 | Bausch Health Ireland Limited | Pharmaceutical formulations containing corticosteroids for topical administration |
| HUE050603T2 (hu) * | 2015-06-18 | 2020-12-28 | Bausch Health Ireland Ltd | Egy kortikoszteroidot és egy retinoidot tartalmazó topikális készítmények psoriasis kezelésére |
| NZ738815A (en) * | 2015-07-13 | 2019-10-25 | Dr Reddy’s Laboratories Ltd | Topical retinoid compositions |
| US11311482B2 (en) * | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
| JP7410720B2 (ja) * | 2017-05-12 | 2024-01-10 | ボシュ ヘルス アイルランド リミテッド | 皮膚疾患を治療するための局所組成物および方法 |
| EP3641728B9 (en) * | 2017-06-23 | 2021-06-30 | Laboratorios SALVAT, S.A. | An oil-in-water nanoemulsion composition of clobetasol |
| US10653656B2 (en) | 2018-04-05 | 2020-05-19 | Bausch Health Ireland Limited | Topical pharmaceutical compositions for treating skin conditions |
| EP3775116A4 (en) * | 2018-04-05 | 2022-03-23 | Bausch Health Ireland Limited | POLYMER EMULSION DISTRIBUTION SYSTEMS |
| JP2022525221A (ja) * | 2019-03-14 | 2022-05-11 | クレシタ セラピューティクス インコーポレイテッド | 洗い流し組成物および活性剤を送達するためのそれらの使用 |
| KR102327827B1 (ko) | 2019-11-01 | 2021-11-18 | 한국과학기술연구원 | 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물 |
| KR102451304B1 (ko) | 2020-09-14 | 2022-10-07 | 한국과학기술연구원 | 꿩의다리속 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR102527907B1 (ko) | 2020-09-14 | 2023-05-03 | 한국과학기술연구원 | 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR102461001B1 (ko) | 2020-09-14 | 2022-11-01 | 한국과학기술연구원 | 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| KR20230041257A (ko) | 2021-09-17 | 2023-03-24 | 한국과학기술연구원 | 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물 |
| KR20230041255A (ko) | 2021-09-17 | 2023-03-24 | 한국과학기술연구원 | 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물 |
| CN113975249B (zh) * | 2021-10-14 | 2023-01-03 | 中山大学·深圳 | Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用 |
| CN113712918A (zh) * | 2021-10-28 | 2021-11-30 | 济南纽华医药科技有限公司 | 一种阿普斯特微乳及其制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU75903A1 (da) | 1976-09-29 | 1978-05-16 | ||
| NL7105591A (en) | 1971-04-24 | 1972-10-26 | Topical antiphlogistic compsns - contng 3, 20-diketo-9 alpha, 11 beta-dichloro - 16 alpha, 17 alpha-dimethyl-21-hydroxy pregna-1,4- | |
| DE2655570A1 (de) | 1975-12-12 | 1977-06-16 | Ciba Geigy Ag | Neue polyhalogensteroide und verfahren zu ihrer herstellung |
| US4048310A (en) | 1976-02-24 | 1977-09-13 | E. R. Squibb & Sons, Inc. | Topical steroid formulation in form of lotion or cream |
| US4083974A (en) | 1977-03-07 | 1978-04-11 | The Upjohn Company | Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether |
| JPS5850964B2 (ja) | 1978-03-07 | 1983-11-14 | 東興薬品工業株式会社 | ステロイド含有クリ−ム製剤およびその製造方法 |
| US4299828A (en) | 1979-05-31 | 1981-11-10 | E. R. Squibb & Sons, Inc. | Corticosteroid stick formulations |
| US4233295A (en) | 1979-05-31 | 1980-11-11 | E. R. Squibb & Sons, Inc. | Corticosteroid formulations containing sebacate carrier |
| AU5794680A (en) | 1979-05-31 | 1980-12-04 | E.R. Squibb & Sons, Inc. | Corticosteroid stick formulations |
| CH649923A5 (de) | 1980-10-06 | 1985-06-28 | Glaxo Group Ltd | Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide. |
| JPS58225009A (ja) | 1982-06-23 | 1983-12-27 | Shionogi & Co Ltd | コルチコステロイド外用製剤 |
| DE3225848A1 (de) | 1982-07-07 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Kortikoidhaltige zubereitung zur topischen applikation |
| GB8401965D0 (en) | 1984-01-25 | 1984-02-29 | Beecham Group Plc | Composition |
| CA1303991C (en) | 1986-03-31 | 1992-06-23 | Chung H. Cheng | Composition and method for delivering a steroid active ingredient |
| US5019569A (en) | 1986-11-03 | 1991-05-28 | Ortho Pharmaceutical Corporation | Reversal of glucocorticoid-induced skin atrophy |
| JPH0676327B2 (ja) | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイド軟膏製剤 |
| JPH0676328B2 (ja) | 1987-04-14 | 1994-09-28 | 株式会社大塚製薬工場 | ステロイドクリ−ム製剤 |
| JPH07116026B2 (ja) | 1987-07-07 | 1995-12-13 | 株式会社資生堂 | ジクロフェナックナトリウム含有乳化外用剤 |
| US5422361A (en) | 1989-12-20 | 1995-06-06 | Schering Corporation | Stable cream and lotion bases for lipophilic drug compositions |
| ES2082196T3 (es) | 1990-03-02 | 1996-03-16 | Shiseido Co Ltd | Composicion de emulsion de aceite en agua que contiene un analgesico antiflogistico no esteroideo. |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| TW218849B (da) * | 1991-05-17 | 1994-01-11 | Bristol Myers Squibb Co | |
| WO1998036753A1 (en) | 1997-02-20 | 1998-08-27 | Allergan Sales,Inc. | Tazarotene and corticosteroid treatment for psoriasis |
| SE9800729L (sv) | 1998-03-06 | 1999-09-07 | Scotia Lipidteknik Ab | Ny topikal formulering I |
| GB9823036D0 (en) | 1998-10-22 | 1998-12-16 | Glaxo Group Ltd | Fluticasone lotion having improved vasoconstrictor activity |
| WO2000047211A1 (en) * | 1999-02-12 | 2000-08-17 | Susan Bershad | Short contact treatment of psoriasis with topical retinoids |
| US6730308B1 (en) * | 1999-03-08 | 2004-05-04 | Allergan, Inc. | Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage |
| US6479058B1 (en) | 1999-09-02 | 2002-11-12 | Mccadden Michael E. | Composition for the topical treatment of poison ivy and other forms of contact dermatitis |
| US6656928B1 (en) | 1999-09-02 | 2003-12-02 | Mccadden Michael E. | Composition for the topical treatment of rashes, dermatoses and lesions |
| US6387383B1 (en) | 2000-08-03 | 2002-05-14 | Dow Pharmaceutical Sciences | Topical low-viscosity gel composition |
| EP1331927B1 (en) * | 2000-10-27 | 2007-12-12 | Leo Pharma A/S | Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid |
| US6709663B2 (en) | 2001-08-31 | 2004-03-23 | Healthpoint, Ltd. | Multivesicular emulsion drug delivery systems |
| US6765001B2 (en) | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
| US7544674B2 (en) | 2002-10-25 | 2009-06-09 | Galderma S.A. | Topical skin care composition |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| CN1210034C (zh) * | 2002-12-06 | 2005-07-13 | 重庆华邦制药股份有限公司 | 治疗银屑病的药物组合物 |
| WO2004058262A1 (en) | 2002-12-31 | 2004-07-15 | Wockhardt Limited | Benzoquinolizine-2-carboxylic acid-containing compositions |
| JP2004359585A (ja) | 2003-06-03 | 2004-12-24 | Medorekkusu:Kk | 被膜形成型の副腎皮質ステロイド薬含有外用製剤 |
| CN1210041C (zh) * | 2003-09-29 | 2005-07-13 | 中国医学科学院皮肤病研究所 | 治疗痤疮的复方外用药物 |
| CN1210035C (zh) * | 2003-09-29 | 2005-07-13 | 中国医学科学院皮肤病研究所 | 治疗银屑病的复方外用药物 |
| US8741333B2 (en) | 2004-06-07 | 2014-06-03 | Nuvo Research Inc. | Compositions and methods for treating dermatitis or psoriasis |
| JPWO2006098353A1 (ja) | 2005-03-15 | 2008-08-28 | 協和醗酵工業株式会社 | 外用剤 |
| TW200740441A (en) | 2005-06-17 | 2007-11-01 | Combinatorx Inc | Methods and reagents for the treatment of inflammatory disorders |
| EP1968541A2 (en) | 2005-12-14 | 2008-09-17 | Zars, Inc. | Compositions and methods for dermal delivery of drugs |
| SI2494959T1 (sl) | 2006-07-05 | 2015-04-30 | Foamix Pharmaceuticals Ltd. | Penilno sredstvo dikarboksilne kisline in njega farmacevtski sestavki |
| WO2008152444A2 (en) | 2006-11-29 | 2008-12-18 | Foamix Ltd. | Foamable waterless compositions with modulating agents |
| US20100240621A1 (en) | 2007-09-10 | 2010-09-23 | Glenmark Pharmaceuticals Ltd. | Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid |
| WO2009084020A2 (en) | 2007-10-18 | 2009-07-09 | Glenmark Pharmaceuticals Limited | Topical composition comprising halobetasol and salicylic acid |
| US20110212157A1 (en) | 2008-06-26 | 2011-09-01 | Anterios, Inc. | Dermal delivery |
| PT2400951T (pt) | 2009-02-25 | 2018-11-26 | Mayne Pharma Llc | Composições de espuma tópica |
| US20130310355A1 (en) | 2009-12-15 | 2013-11-21 | Young Pharmaceuticals, Inc. | Low toxicity topical active agent delivery system |
| US9782341B2 (en) | 2010-10-15 | 2017-10-10 | John E. Kulesza | Delivery of hydrophobic bioactive agents |
| KR101962658B1 (ko) * | 2010-11-04 | 2019-07-31 | 442 벤쳐스 엘엘씨 | 피부 상태를 치료하기 위한 조성물 및 방법 |
| US8809307B2 (en) * | 2010-11-22 | 2014-08-19 | Dow Pharmaceutical Sciences, Inc. | Pharmaceutical formulations containing corticosteroids for topical administration |
| US9034926B2 (en) * | 2010-12-30 | 2015-05-19 | Nicholas V. Perricone | Topical nitrone spin trap compositions for psoriasis |
| WO2012167018A1 (en) | 2011-06-03 | 2012-12-06 | Allergan, Inc. | Targeted delivery of retinoid compounds to the sebaceous glands |
| BR112014015578A8 (pt) * | 2012-01-09 | 2017-07-04 | Almirall Sa | composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide |
| US8962028B2 (en) | 2012-10-18 | 2015-02-24 | MiCal Pharmaceuticals LLC—H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limited Liability Company | Topical steroid composition and method |
| CN104288157B (zh) * | 2013-01-29 | 2018-04-13 | 江苏知原药业有限公司 | 包含丙酸氯倍他索和维a酸的固体分散体及其制备方法 |
| EP3049063A1 (en) * | 2013-09-25 | 2016-08-03 | Sun Pharmaceutical Industries Ltd | Topical spray composition of halobetasol |
| US20190133943A1 (en) | 2015-06-18 | 2019-05-09 | Valeant Pharmaceuticals North America | Topical compositions and methods for treating skin diseases |
| HUE050603T2 (hu) | 2015-06-18 | 2020-12-28 | Bausch Health Ireland Ltd | Egy kortikoszteroidot és egy retinoidot tartalmazó topikális készítmények psoriasis kezelésére |
| JP7410720B2 (ja) | 2017-05-12 | 2024-01-10 | ボシュ ヘルス アイルランド リミテッド | 皮膚疾患を治療するための局所組成物および方法 |
| US11311482B2 (en) * | 2017-05-12 | 2022-04-26 | Bausch Health Us, Llc | Topical compositions and methods for treating skin diseases |
-
2016
- 2016-06-06 HU HUE16729470A patent/HUE050603T2/hu unknown
- 2016-06-06 ES ES16729470T patent/ES2812451T3/es active Active
- 2016-06-06 SI SI201630936T patent/SI3310389T1/sl unknown
- 2016-06-06 BR BR112017027332-2A patent/BR112017027332B1/pt active IP Right Grant
- 2016-06-06 LT LTEP16729470.1T patent/LT3310389T/lt unknown
- 2016-06-06 MX MX2017015990A patent/MX2017015990A/es active IP Right Grant
- 2016-06-06 CN CN201680035629.7A patent/CN108282998B/zh active Active
- 2016-06-06 US US15/173,961 patent/US10251895B2/en active Active
- 2016-06-06 WO PCT/US2016/035991 patent/WO2016205001A1/en active Application Filing
- 2016-06-06 RS RS20200997A patent/RS60672B1/sr unknown
- 2016-06-06 PL PL16729470T patent/PL3310389T3/pl unknown
- 2016-06-06 JP JP2017563568A patent/JP6997624B2/ja active Active
- 2016-06-06 EP EP16729470.1A patent/EP3310389B1/en active Active
- 2016-06-06 CA CA2988577A patent/CA2988577A1/en active Pending
- 2016-06-06 KR KR1020187001229A patent/KR102643849B1/ko active IP Right Grant
- 2016-06-06 PT PT167294701T patent/PT3310389T/pt unknown
- 2016-06-06 DK DK16729470.1T patent/DK3310389T3/da active
- 2016-06-06 KR KR1020247006984A patent/KR20240035898A/ko active Search and Examination
- 2016-06-06 AU AU2016279801A patent/AU2016279801B2/en active Active
-
2018
- 2018-02-23 US US15/903,785 patent/US10426787B2/en active Active
-
2019
- 2019-04-08 US US16/377,540 patent/US20190231797A1/en not_active Abandoned
-
2020
- 2020-08-04 CY CY20201100719T patent/CY1123354T1/el unknown
- 2020-08-10 HR HRP20201250TT patent/HRP20201250T1/hr unknown
-
2021
- 2021-01-21 US US17/154,591 patent/US11679115B2/en active Active
- 2021-07-02 US US17/366,871 patent/US11679116B2/en active Active
-
2022
- 2022-11-23 US US17/993,817 patent/US11648256B2/en active Active
-
2023
- 2023-05-04 US US18/312,162 patent/US20230355640A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3310389T3 (da) | Topiske sammensætninger omfattende et kortikosteroid og et retinoid til behandling af psoriasis | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3426859T3 (da) | Gipspanel, anvendelse af et sådant panel og fremgangsmåde til fremstilling af et sådant panel | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3155101T3 (da) | Sammensætninger og fremgangsmåder til ekspression af CRISPR-leder-RNA´er under anvendelse af H1-promotoren | |
| DK3145437T3 (da) | Ortodontisk apparatur og fremgangsmåde til fremstilling af et ortodontisk apparatur | |
| DK3143217T3 (da) | Akustisk panel og fremgangsmåde til at forbedre æstetikken af et akustisk panel | |
| DK3350201T3 (da) | Manipulerede fytaser og fremgangsmåder til anvendelse af samme | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3229840T5 (da) | 3,5-dihydroxy-4-isopropyl-trans-stilben til anvendelse i topisk behandling af akne | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3081263T3 (da) | Sammensætninger og redskaber til behandling af glaukom | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3212776T3 (da) | Sammensætninger og fremgangsmåder i forbindelse med beta-glucosidase | |
| DK3394259T3 (da) | Sammensætninger og fremgangsmåder til reducering af tau-ekspression | |
| DK3288379T3 (da) | Peptidsammensætninger og anvendelsesmåder | |
| DK3240821T3 (da) | Lavdosis gashydrathæmmersammensætning og tilhørende fremgangsmåde | |
| DK3122743T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi |